BLC
CPRX

Brown, Lisle/Cummings’s Catalyst Pharmaceutical CPRX Stock Holding History

Brown, Lisle/Cummings’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$644 Buy
+26
New +$619 ﹤0.01% 970

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Brown, Lisle/Cummings's CPRX Position: Q1 2026 in Review

Brown, Lisle/Cummings opened a new position in Catalyst Pharmaceutical (CPRX) in Q1 2026: 26 shares worth $644. The stake represents ﹤0.01% of the portfolio and ranks #970 among its holdings.

380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Brown, Lisle/Cummings held 26 shares of Catalyst Pharmaceutical worth $644 as of Q1 2026.
  • Catalyst Pharmaceutical was a new Brown, Lisle/Cummings position in Q1 2026.
  • Catalyst Pharmaceutical made up ﹤0.01% of Brown, Lisle/Cummings's portfolio in Q1 2026, its #970 holding.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Brown, Lisle/Cummings's 13F filing for Q1 2026, filed 20 Apr 2026.